Jonathan Phillips

Jonathan Phillips Email and Phone Number

Head of Pharmacology and Toxicology @ Intellia Therapeutics, Inc.
Cambridge, MA, US
Jonathan Phillips's Location
Cambridge, Massachusetts, United States, United States
Jonathan Phillips's Contact Details
About Jonathan Phillips

At Intellia Therapeutics, I'm leading nonclinical strategy as Vice President of Pharmacology & Toxicology. My experience developing gene editing therapies began at Vertex where I co-authored first-in-human applications for CTX001 (CASGEVY), in partnership with CRISPR Therapeutics. I've also built and led several translational and investigative safety teams during my time with Boehringer Ingelheim. Prior to industry, I was a Bioastronautics Fellow at NASA Ames Research Center in Mountain View, CA where we investigated basic principles of mechanobiology in space travel environments. I hold a PhD in cell biology from UMass-Worcester, where I was a NASA funded candidate. My 20+ year scientific record includes dozens of peer reviewed publications, book chapters, and invited presentations.

Jonathan Phillips's Current Company Details
Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc.

View
Head of Pharmacology and Toxicology
Cambridge, MA, US
Website:
intelliatx.com
Employees:
446
Jonathan Phillips Work Experience Details
  • Intellia Therapeutics, Inc.
    Head Of Pharmacology And Toxicology
    Intellia Therapeutics, Inc.
    Cambridge, Ma, Us
  • Intellia Therapeutics, Inc.
    Head Of Pharmacology & Toxicology
    Intellia Therapeutics, Inc. Apr 2019 - Present
    Cambridge, Massachusetts, Us
    Head of pharmacology & toxicology for the company leading the world to genome editing cures. Led nonclinical development strategy enabling successful clinical starts for NTLA-2001 (ATTR), NTLA-5001 (AML), NTLA-2002 (HAE), and NTLA-3001 (AATD). We employ a modular genome editing platform to create diverse in vivo and cell therapies for a range of disease indications.
  • Eclipse Scientific Editing
    Managing Editor
    Eclipse Scientific Editing May 2005 - Present
    Us
    Editing firm specializing in polished biomedical communication. Long track record of repeat Japanese and European clients. Services include reviewing and revising peer reviewed manuscripts, grants, posters and slides.
  • Vertex Pharmaceuticals
    Fellow
    Vertex Pharmaceuticals Aug 2016 - Apr 2019
    Boston, Ma, Us
    Discovery toxicologist for Boston R&D portfolio. Program team nonclinical representative for CTX001 (exa-cel) to treat sickle cell disease and beta-thalassemia. Co-authored first-ever IND and CTA for a CRISPR/Cas9 edited investigative product.
  • Boehringer Ingelheim
    Senior Principal Scientist
    Boehringer Ingelheim May 2015 - Jul 2016
    Ingelheim Am Rhein, Rhineland-Palatinate, De
    Built a Biophysics, Modeling & Simulation team focused on toxicity insights through quantitative systems biology, fueled by a hybrid computational and experimental laboratory.
  • Boehringer Ingelheim
    Principal Scientist
    Boehringer Ingelheim Jun 2010 - May 2015
    Ingelheim Am Rhein, Rhineland-Palatinate, De
    Built and led safety biomarker laboratory. Research toxicologist for oncology biologics (Vienna, Austria). US R&D site liaison to global clinical biomarker team in Biberach, Germany.
  • Boehringer Ingelheim
    Expatriate Lab Leader, Clinical Biomarkers, Dmpk-De
    Boehringer Ingelheim Jun 2012 - Jun 2013
    Ingelheim Am Rhein, Rhineland-Palatinate, De
    Contributed to strategic aspects of implementing biomarkers onto clinical studies. Team member for Phase 0 exploratory biomarker trials and priority discovery projects.
  • Boehringer Ingelheim
    Senior Scientist, Integrative Toxicology
    Boehringer Ingelheim Dec 2006 - Jun 2010
    Ingelheim Am Rhein, Rhineland-Palatinate, De
    Founded a cell biology lab to support mechanistic toxicology investigations. Managed four scientists and hosted various visiting experts, interns, postdocs and co-ops depending on project demands.
  • The Critical Path Institute
    Nephrotoxicity Working Group Co-Chair
    The Critical Path Institute Jan 2010 - Jan 2012
    Achieved first-ever translational safety biomarker Letters of Support from FDA and EMA.Led team responsible for submissions supporting rat urinary NGAL and osteopontin as biomarkers of drug induced kidney injury. Member of Qualification Leadership Team (QLT) responsible for delivering biomarker qualification briefing materials, data, face-to-face presentations and regulatory interactions to FDA, EMA, and, PMDA.
  • Nasa Ames Research Center
    Postdoctoral Fellow
    Nasa Ames Research Center Sep 2004 - Dec 2006
    Moffett Field, California, Us
    Fellowship awarded by USRA to join the Gravitational Biology Research Branch, studying mechanisms of microgravity associated bone loss. Managed transgenic colony used to study the role of molecular mechanotransducers in space travel. (See also: Matrix Biology (2008) 27:609-618). Contributed to joint spaceflight program with the Russian Institute of Biomedical Problems studying tissue regeration in lower vertebrates under microgravitational conditions. (See also: J of Gravit Physiol (2006) 13:185-188 & 193-196). Awarded second fellowship to lead research focused on p53 as a nexus of gravitational mechanosensing, cellular proliferation and radiation responsiveness. (See also: Radiation Research (2009) 171:283-289)
  • Beth Israel Deaconess Medical Center
    Research Associate
    Beth Israel Deaconess Medical Center Dec 1997 - Jul 1999
    Boston, Ma, Us
    Ann Thorac Surg (2001) 72:555-563
  • Genome Therapeutics Corp
    Scientist
    Genome Therapeutics Corp Jul 1996 - Dec 1997
    J Bacteriol (2001) 183:4823-38.

Jonathan Phillips Skills

Drug Development In Vitro Biotechnology Biomarker Discovery Toxicology Cell Drug Discovery Molecular Biology Assay Development Pharmaceutical Industry Life Sciences Biochemistry Clinical Development Biomarker Development Sandwiches Translational Medicine Tissue Engineering Emotional Intelligence Fantasy Baseball Biomarkers Cell Biology Tissue Culture Oncology Science Journalism Regulatory Requirements Pharmacokinetics Non Clinical Translational Science Data Mining Analytics Regulatory Guidelines

Jonathan Phillips Education Details

  • University Of Massachusetts Graduate School Of Biomedical Sciences
    University Of Massachusetts Graduate School Of Biomedical Sciences
    Mechanobiology
  • Florida Institute Of Technology
    Florida Institute Of Technology
    Molecular Biology
  • Florida Institute Of Technology
    Florida Institute Of Technology
    Pre-Medicine/Pre-Medical Studies

Frequently Asked Questions about Jonathan Phillips

What company does Jonathan Phillips work for?

Jonathan Phillips works for Intellia Therapeutics, Inc.

What is Jonathan Phillips's role at the current company?

Jonathan Phillips's current role is Head of Pharmacology and Toxicology.

What is Jonathan Phillips's email address?

Jonathan Phillips's email address is jo****@****hoo.com

What schools did Jonathan Phillips attend?

Jonathan Phillips attended University Of Massachusetts Graduate School Of Biomedical Sciences, Florida Institute Of Technology, Florida Institute Of Technology.

What are some of Jonathan Phillips's interests?

Jonathan Phillips has interest in Health.

What skills is Jonathan Phillips known for?

Jonathan Phillips has skills like Drug Development, In Vitro, Biotechnology, Biomarker Discovery, Toxicology, Cell, Drug Discovery, Molecular Biology, Assay Development, Pharmaceutical Industry, Life Sciences, Biochemistry.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.